Represent

Lobbying
Lobbying by Merck & Co, Inc.

Lobbying Relationship

Client

Merck & Co, Inc.

More records

Lobbying firm

Merck & Co, Inc.

More records

H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms.
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 5376, (117th Cong.) Build Back Better Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2024 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP); Medicaid Best Price Policy; Medicaid - Centers for Medicare & Medicaid Services notice of proposed rulemaking: "Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program."
Issues relating to, Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.

Duration: January 1, 2008 to present

General Issues: Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Agriculture, Consumer Issues/Safety/Protection, Animals, Intelligence and Surveillance, Budget/Appropriations, Trade (Domestic & Foreign), Manufacturing, Medical/Disease Research/Clinical Labs, Law Enforcement/Crime/Criminal Justice, Financial Institutions/Investments/Securities, Chemicals/Chemical Industry

Spending: about $116,132,510 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives, White House Office, Commerce - Dept of (DOC), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), U.S. Senate,, U.S. Trade Representative (USTR),

Bills mentioned

S.469: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

S.637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017

Sponsor: Ron Wyden (D-Ore.)

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina...

Sponsor: Ron Johnson (R-Wis.)

H.R.878: Right to Try Act of 2017

Sponsor: Andy Biggs (R-Ariz.)

H.R.2028: Healthy Relationships Act of 2017

Sponsor: Randy Hultgren (R-Ill.)

S.CON.RES.3: A concurrent resolution setting forth the congressional budget for the...

Sponsor: Michael B. Enzi (R-Wyo.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

H.R.3678: Preserving Access to Orphan Drugs Act of 2015

Sponsor: Mike Kelly (R-Pa.)

H.R.5122: To prohibit further action on the proposed rule regarding testing of...

Sponsor: Larry Bucshon (R-Ind.)

H.R.2028: Further Continuing and Security Assistance Appropriations Act, 2017

Sponsor: Mike Simpson (R-Idaho)

H.R.4187: Secure and Protect Americans' Data Act

Sponsor: Jan Schakowsky (D-Ill.)

S.3056: CREATES Act of 2016

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1074: National Diabetes Clinical Care Commission Act

Sponsor: Pete Olson (R-Texas)

S.539: National Diabetes Clinical Care Commission Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.3322: Eliminating Disparities in Diabetes Prevention, Access, and Care Act of...

Sponsor: Diana DeGette (D-Colo.)

H.R.4187: DISARM Act of 2014

Sponsor: Peter Roskam (R-Ill.)

H.R.3116: MODDERN Cures Act of 2013

Sponsor: Leonard Lance (R-N.J.)

H.R.2925: Strengthening Medicare Anti-Fraud Measures Act of 2013

Sponsor: Kevin Brady (R-Texas)

S.1128: Preserving Access to Orphan Drugs Act of 2013

Sponsor: Patrick J. Toomey (R-Pa.)

H.R.3299: Strengthening Public Health Emergency Response Act of 2016

Sponsor: Susan Brooks (R-Ind.)

S.1128: Early Pell Promise Act

Sponsor: Debbie Stabenow (D-Mich.)

H.R.9: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

S.632: STRONG Patents Act of 2015

Sponsor: Christopher A. Coons (D-Del.)

S.1200: Fairness to Pet Owners Act of 2015

Sponsor: Richard Blumenthal (D-Conn.)

H.R.2: Medicare Access and CHIP Reauthorization Act of 2015

Sponsor: Michael C. Burgess (R-Texas)

H.R.5780: Utah Public Lands Initiative Act

Sponsor: Rob Bishop (R-Utah)

S.320: Medical Innovation Act of 2015

Sponsor: Elizabeth Warren (D-Mass.)

H.R.3309: Flex-IT 2 Act

Sponsor: Renee Ellmers (R-N.C.)

H.R.5780: Protecting the Integrity of Medicare Act of 2014

Sponsor: Kevin Brady (R-Texas)

S.351: Protecting Seniors' Access to Medicare Act of 2013

Sponsor: John Cornyn (R-Texas)

H.R.351: Protecting Seniors' Access to Medicare Act of 2013

Sponsor: Phil Roe (R-Tenn.)

H.R.4302: Protecting Access to Medicare Act of 2014

Sponsor: Joe Pitts (R-Pa.)

H.R.3167: Playing Fair on Trade and Innovation Act

Sponsor: Lee Terry (R-Neb.)

H.R.3309: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

S.1720: Patent Transparency and Improvements Act of 2013

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.3204: Drug Quality and Security Act

Sponsor: Fred Upton (R-Mich.)

S.1413: FDA User Fee Protection Act

Sponsor: Mark Pryor (D-Ark.)

H.R.2775: Continuing Appropriations Act, 2014

Sponsor: Diane Black (R-Tenn.)

H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013

Sponsor: Robert E. Latta (R-Ohio)

S.959: Pharmaceutical Quality, Security, and Accountability Act

Sponsor: Tom Harkin (D-Iowa)

S.957: Drug Supply Chain Security Act

Sponsor: Michael Bennet (D-Colo.)

H.R.1407: Animal Drug User Fee Amendments of 2013

Sponsor: John Shimkus (R-Ill.)

H.R.3381: Viral Hepatitis Testing Act of 2011

Sponsor: Bill Cassidy (R-La.)

H.R.452: Medicare Decisions Accountability Act of 2011

Sponsor: Phil Roe (R-Tenn.)

H.R.5: Protecting Access to Healthcare Act

Sponsor: Phil Gingrey (R-Ga.)

S.668: Health Care Bureaucrats Elimination Act

Sponsor: John Cornyn (R-Texas)

H.R.5651: Food and Drug Administration Reform Act of 2012

Sponsor: Fred Upton (R-Mich.)

S.3187: Food and Drug Administration Safety and Innovation Act

Sponsor: Tom Harkin (D-Iowa)

H.R.2245: Preserving Access to Life-Saving Medications Act of 2011

Sponsor: Diana DeGette (D-Colo.)

S.296: Preserving Access to Life-Saving Medications Act

Sponsor: Amy Klobuchar (D-Minn.)

S.810: Great Ape Protection and Cost Savings Act of 2011

Sponsor: Maria Cantwell (D-Wash.)

H.R.2182: Generating Antibiotic Incentives Now Act of 2011

Sponsor: Phil Gingrey (R-Ga.)

H.R.942: American Research and Competitiveness Act of 2011

Sponsor: Kevin Brady (R-Texas)

S.1577: GROWTH Act

Sponsor: Max Baucus (D-Mont.)

H.R.965: Preservation of Antibiotics for Medical Treatment Act of 2011

Sponsor: Louise M. Slaughter (D-N.Y.)

S.1211: Preservation of Antibiotics for Medical Treatment Act of 2011

Sponsor: Dianne Feinstein (D-Calif.)

H.R.1406: Fairness to Pet Owners Act of 2011

Sponsor: Jim Matheson (D-Utah)

H.R.2759: Business Transparency on Trafficking and Slavery Act

Sponsor: Carolyn B. Maloney (D-N.Y.)

H.R.3080: United States-Korea Free Trade Agreement Implementation Act

Sponsor: Eric Cantor (R-Va.)

H.R.1249: Leahy-Smith America Invents Act

Sponsor: Lamar Smith (R-Texas)

H.R.2112: Consolidated and Further Continuing Appropriations Act, 2012

Sponsor: Jack Kingston (R-Ga.)

S.1213: Patient-Centered Outcomes Research Act of 2009

Sponsor: Max Baucus (D-Mont.)

S.301: Physician Payments Sunshine Act of 2009

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.1679: Affordable Health Choices Act

Sponsor: Tom Harkin (D-Iowa)

S.1796: America's Healthy Future Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4872: Health Care and Education Reconciliation Act of 2010

Sponsor: John M. Spratt Jr. (D-S.C.)

S.515: Patent Reform Act of 2009

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1260: Patent Reform Act of 2009

Sponsor: John Conyers Jr. (D-Mich.)

H.R.422: To amend the Internal Revenue Code of 1986 to extend the research credit...

Sponsor: Kendrick B. Meek (D-Fla.)

S.1203: GROWTH Act

Sponsor: Max Baucus (D-Mont.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

S.23: America Invents Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.4853: Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act...

Sponsor: James L. Oberstar (D-Minn.)

S.RES.531: A resolution supporting the goals and ideals of National Hepatitis...

Sponsor: Dianne Feinstein (D-Calif.)

H.R.3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009

Sponsor: Michael M. Honda (D-Calif.)

S.3677: Financial Services and General Government Appropriations Act, 2011

Sponsor: Richard J. Durbin (D-Ill.)

S.369: Preserve Access to Affordable Generics Act

Sponsor: Herb Kohl (D-Wis.)

H.R.5893: Investing in American Jobs and Closing Tax Loopholes Act of 2010

Sponsor: Sander M. Levin (D-Mich.)

H.R.5809: Diesel Emissions Reduction Act of 2010

Sponsor: Jay Inslee (D-Wash.)

S.3397: Secure and Responsible Drug Disposal Act of 2010

Sponsor: Amy Klobuchar (D-Minn.)

H.R.4173: Dodd-Frank Wall Street Reform and Consumer Protection Act

Sponsor: Barney Frank (D-Mass.)

H.R.2346: Supplemental Appropriations Act, 2009

Sponsor: David R. Obey (D-Wis.)

S.2029: Physician Payments Sunshine Act of 2007

Sponsor: Charles E. Grassley (R-Iowa)

S.1145: Patent Reform Act of 2007

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1908: Patent Reform Act of 2007

Sponsor: Howard L. Berman (D-Calif.)

H.R.4: Medicare Prescription Drug Price Negotiation Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.250: Medicare Enhancements for Needed Drugs Act of 2007

Sponsor: Olympia J. Snowe (R-Maine)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

H.R.3358: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Tom Cole (R-Okla.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.2296: More Efficient Tools to Realize Information for Consumers Act

Sponsor: Jan Schakowsky (D-Ill.)

H.R.4100: DISARM Act of 2019

Sponsor: Danny K. Davis (D-Ill.)

S.1712: DISARM Act of 2019

Sponsor: Johnny Isakson (R-Ga.)

H.R.4455: BIOSIM Act

Sponsor: Kurt Schrader (D-Ore.)

H.R.4597: ACCESS for Biosimilars Act of 2019

Sponsor: Scott Peters (D-Calif.)

H.R.4629: Star Rating for Biosimilars Act

Sponsor: Paul Tonko (D-N.Y.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the...

Sponsor: Michael C. Burgess (R-Texas)

S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019

Sponsor: Amy Klobuchar (D-Minn.)

S.475: RxCAP Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.1437: Drug-price Transparency in Communications (DTC) Act

Sponsor: Richard J. Durbin (D-Ill.)

H.R.2069: SPIKE Act

Sponsor: Steven Horsford (D-Nev.)

S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive...

Sponsor: Ron Wyden (D-Ore.)

S.1209: REMEDY Act

Sponsor: Bill Cassidy (R-La.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019

Sponsor: Peter Welch (D-Vt.)

H.R.1046: Medicare Negotiation and Competitive Licensing Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

S.476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Sponsor: Ron Wyden (D-Ore.)

H.R.748: CARES Act

Sponsor: Joe Courtney (D-Conn.)

H.R.5076: Protecting Seniors Through Immunization Act of 2019

Sponsor: Donna Shalala (D-Fla.)

H.R.6197: CFTC Reauthorization Act of 2019

Sponsor: Collin C. Peterson (D-Minn.)

H.R.8061: Community Immunity During COVID–19 Act of 2020

Sponsor: Lauren Underwood (D-Ill.)

H.R.19: Lower Costs, More Cures Act of 2019

Sponsor: Greg Walden (R-Ore.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

H.R.8920: The PASTEUR Act

Sponsor: Mike Doyle (D-Pa.)

S.4760: The PASTEUR Act

Sponsor: Michael Bennet (D-Colo.)

H.R.597: Pandemic Treatment Access and Affordability Act of 2021

Sponsor: Jan Schakowsky (D-Ill.)

H.R.959: Black Maternal Health Momnibus Act of 2021

Sponsor: Lauren Underwood (D-Ill.)

H.R.1319: American Rescue Plan Act of 2021

Sponsor: John Yarmuth (D-Ky.)

H.R.1550: PREVENT HPV Cancers Act of 2021

Sponsor: Kathy Castor (D-Fla.)

H.R.2061: Advancing Emergency Preparedness Through One Health Act of 2021

Sponsor: Kurt Schrader (D-Ore.)

H.R.133: David’s Law

Sponsor: Sheila Jackson Lee (D-Texas)

S.476: Pandemic Heroes Compensation Act of 2021

Sponsor: Tammy Duckworth (D-Ill.)

H.R.1978: Protecting Seniors Through Immunization Act of 2021

Sponsor: Ann McLane Kuster (D-N.H.)

H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act...

Sponsor: David Cicilline (D-R.I.)

H.R.3173: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Suzan K. DelBene (D-Wash.)

S.1435: Affordable Prescriptions for Patients Act of 2021

Sponsor: John Cornyn (R-Texas)

S.2076: PASTEUR Act of 2021

Sponsor: Michael Bennet (D-Colo.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.19: Lower Costs, More Cures Act of 2021

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.4100: CORPS Act

Sponsor: David E. Price (D-N.C.)

S.1712: A bill to amend subtitle A of title II of division A of the CARES Act to...

Sponsor: Mike Braun (R-Ind.)

S.1895: A bill to require the Secretary of Health and Human Services to award...

Sponsor: Ben Ray Luján (D-N.M.)

H.R.5260: Reduced Costs and Continued Cures Act

Sponsor: Scott Peters (D-Calif.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

S.2543: A bill to require a study on the national security implications of the...

Sponsor: Bill Hagerty (R-Tenn.)

H.R.5801: HELP Copays Act

Sponsor: A. Donald McEachin (D-Va.)

S.2774: Pride in Patent Ownership Act

Sponsor: Patrick J. Leahy (D-Vt.)

S.2891: Restoring the America Invents Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.3932: PASTEUR Act of 2021

Sponsor: Mike Doyle (D-Pa.)

S.2079: Stop Settlement Slush Funds Act of 2021

Sponsor: Tommy Tuberville (R-Ala.)

H.R.4127: DISARM Act of 2021

Sponsor: Danny K. Davis (D-Ill.)

H.R.6584: DEPICT Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.6963: Accelerated Approval Integrity Act of 2022

Sponsor: Frank Pallone (D-N.J.)

H.R.5416: Give Kids a Chance Act

Sponsor: G. K. Butterfield (D-N.C.)

H.R.7559: Prescription Information Modernization Act of 2022

Sponsor: Mikie Sherrill (D-N.J.)

H.R.7667: Food and Drug Amendments of 2022

Sponsor: Anna G. Eshoo (D-Calif.)

S.4348: FDASLA Act of 2022

Sponsor: Patty Murray (D-Wash.)

H.R.3655: Vaccine Injury Compensation Modernization Act of 2021

Sponsor: Lloyd Doggett (D-Texas)

S.4760: Digital Commodities Consumer Protection Act of 2022

Sponsor: Debbie Stabenow (D-Mich.)

H.R.2716: Honduras Human Rights and Anti-Corruption Act of 2021

Sponsor: Jan Schakowsky (D-Ill.)

H.R.830: Help Ensure Lower Patient Copays Act

Sponsor: Buddy Carter (R-Ga.)

H.R.1418: Animal Drug and Animal Generic Drug User Fee Amendments of 2023

Sponsor: Greg Pence (R-Ind.)

H.R.1503: Prescription Information Modernization Act of 2023

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.1550: Jobs and Opportunities for SNAP Act

Sponsor: Jake LaTurner (R-Kan.)

S.150: Affordable Prescriptions for Patients Act of 2023

Sponsor: John Cornyn (R-Texas)

S.476: Maintaining Investments in New Innovation Act

Sponsor: Robert Menendez (D-N.J.)

S.1844: Animal Drug and Animal Generic Drug User Fee Amendments of 2023

Sponsor: Tammy Baldwin (D-Wis.)

H.R.2679: Pharmacy Benefits Manager Accountability Act

Sponsor: Ann McLane Kuster (D-N.H.)

H.R.2691: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.2816: Pharmacy Benefit Manager Sunshine and Accountability Act

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.2880: Protecting Patients Against PBM Abuses Act

Sponsor: Buddy Carter (R-Ga.)

H.R.2940: Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act...

Sponsor: A. Drew Ferguson (R-Ga.)

S.1355: PASTEUR Act of 2023

Sponsor: Michael Bennet (D-Colo.)

H.R.3290: To amend title III of the Public Health Service Act to ensure...

Sponsor: Larry Bucshon (R-Ind.)

H.R.3285: Fairness for Patient Medications Act

Sponsor: Morgan Griffith (R-Va.)

H.R.4368: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Andy Harris (R-Md.)

S.2131: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Martin Heinrich (D-N.M.)

S.1895: A bill to require the Director of the United States Fish and Wildlife...

Sponsor: Ron Johnson (R-Wis.)

H.R.1613: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Buddy Carter (R-Ga.)

H.R.2666: Medicaid VBPs for Patients Act

Sponsor: Brett Guthrie (R-Ky.)

S.2916: Prescription Information Modernization Act of 2023

Sponsor: Cory Booker (D-N.J.)

H.R.4895: Lowering Drug Costs for American Families Act

Sponsor: Frank Pallone (D-N.J.)

H.R.5376: Share the Savings with Seniors Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.2474: Share the Savings with Seniors Act

Sponsor: John Cornyn (R-Texas)

S.2543: Language Education Data Enhancement Act

Sponsor: Ron Wyden (D-Ore.)

S.2333: Pandemic and All-Hazards Preparedness and Response Act

Sponsor: Bob Casey (D-Pa.)

H.R.6283: Delinking Revenue from Unfair Gouging Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3633: Promoting Resources to Expand Vaccination, Education and New Treatments...

Sponsor: Kathy Castor (D-Fla.)

H.R.7174: To amend title XI of the Social Security Act to equalize the negotiation...

Sponsor: Greg Murphy (R-N.C.)

H.R.7635: The 340B Pharmaceutical Access To Invest in Essential, Needed Treatments...

Sponsor: Doris Matsui (D-Calif.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Robert Filippone	Deputy CoS, Sen. Bob Graham
Katie Oppenheim	Legislative Ass't (Crapo) 10/06-12/10
Jenelle Krishnamoorthy	2004-2006 - Environment,science, technology and health officer, Bureau of South Asia, U.S. State Dept. 2006-2009 - Health Legislative Assistant, Senator Tom Harkin 2010-2015 - Health Policy Director, Senate HELP committee 2004-2006 - Environment,science, technology and health officer, bureau of South Asia, U.S. State Dept. 2006-2009 - Health Legislative Assistant, Senator Tom Harkin 2010-2015 - Health Policy Director, Senate HELP Committee
Courtney Lee-Ashley	Assistant to the Chief of Staff, Senator Ben Nelson (2005-2006)
ELI JOSEPH	Leg. Ass't. White House Office of Leg Affs. Leg. Asst. White House Off. of Leg. Affs. Leg. Ass't. White House Off. of Leg. Affairs Leg. Asst., WH Office of Leg. Affs. Leg. Asst. White House Office of Leg. Affrs. Leg. Asst. White house Off. of Leg Affairs Leg. Ass't. White House Office of Leg. Affs.
Jerome Murray	Legislative Director, Cong. G.K. Butterfield
Angela Stewart	Leg. Counsel, Leg. Asst., Sen. John Warner
Jennifer Bland	Legislative Aid, Senator Thad Cochran
Ryan Ambrose	Clerk, House Energy & Commerce Committee Clerk, House Committee on Energy & Commerce Clerk, House energy & Commerce Committee
Bob Filippone	Deputy COS, Sen. Bob Graham
Liz Schwartz	Legislative Assistant to Sen. Ron H. Johnson 07/2011-06/2014; Senate HELP Committee 06/2014-04/2018
Adam Huftalen	Staff Associate, House Foreign Relations Committee/Rep. Tom Lantos, March 2007 - May 2008
Amelia Breinig	Dir. of Intergovernmental Affairs and Public Engagement, Executive Office of the President; Deputy Press Secretary, Senate finance Committee; Press Aide, Press Secretary, Rep. Terry; Staff Asst., Sen. Fischer
Erin Darling	n/a
Erin Polak	n/a
JAMES CAREY	n/a
Bradley Rossin	n/a
Jason Van Pelt	n/a
Patrick Liedtka	n/a
Tammi Brown	n/a
Bob McMahon	n/a
Anne Esposito	n/a
Robert McMahon	n/a
Victoria Blatter	n/a
Laurie Michel	n/a
Jane Horvath	n/a
G. Lawrence Atkins	n/a
Eli Jospeh	n/a
Ray Quintero	n/a
Paul Ehrlich	n/a
Peter Rubin	n/a
Ian Spatz	n/a
Tom Bombelles	n/a
Spatz	n/a
Courtney Lee- Ashley	n/a
Corey Malmgren	n/a
Brad Rossin	n/a
Bob Filipone	n/a
Bradford Tallamy	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 22. Original Filing: 301573073.xml

Lobbying Issues

H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 5376, (117th Cong.) Build Back Better Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2024 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP); Medicaid Best Price Policy; Medicaid - Centers for Medicare & Medicaid Services notice of proposed rulemaking: "Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program."

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 22. Original Filing: 301536881.xml

Lobbying Issues

H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2023 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2023. Original Filing: 301510029.xml

Lobbying Issues

H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418/S. 1844, Animal Drug User Fee Amendments of 2023 H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Anti-microbial Resistance; Vaccines; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2023 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; Animal Drug User Fee Reauthorization; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues Pharmacy Benefit Manager reforms.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2023. Original Filing: 301485387.xml

Lobbying Issues

H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418/S. 1844, Animal Drug User Fee Amendments of 2023 H.R. 1503/S. 1844, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Anti-microbial Resistance; Vaccines; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; Animal Drug User Fee Reauthorization; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301462097.xml

Lobbying Issues

H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418, Animal Drug User Fee Amendments of 2023 H.R. 1503, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2873, (117th Cong.) Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3932/S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1712, (116th Cong.) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2021 or the PASTEUR Act of 2021 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to: 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Prescription drug cost-sharing; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; Intellectual property and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Pharmacy Benefit Manager (PBM) policy issues.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2023. Original Filing: 301436788.xml

Lobbying Issues

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Animal Drug User Fee Act (P.L. 108-130); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023 Vaccine Injury Compensation Program.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B H.R. 2716, Consolidated Appropriations Act, 2023, provisions relating to Medicare Part D emergency use authorization coverage H.R. 5376, Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2022. Original Filing: 301416566.xml

Lobbying Issues

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Medicare Part D COVID-19 therapeutic coverage issues Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2022. Original Filing: 301388657.xml

Lobbying Issues

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2022. Original Filing: 301369935.xml

Lobbying Issues

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 FDA Emergency Use Authorization issues; COVID-19 Pandemic response; Cost and value of medicines; Drug importation; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Prescription Drug User Fee Authorization (PDUFA VII); Prescription Drug User Fees Act (P.L. 102-571); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2022. Original Filing: 301332993.xml

Lobbying Issues

H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 FDA Emergency Use Authorization issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2022 Budget and Appropriations Legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2021. Original Filing: 301309435.xml

Lobbying Issues

H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act S. 1435, Affordable Prescriptions for Patients Act of 2021 H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2022 Budget and Appropriations Legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301289646.xml

Lobbying Issues

H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2076, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2021. Original Filing: 301261376.xml

Lobbying Issues

H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, AMP-Cap; Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; FY-2022 Budget and Appropriations Legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2021. Original Filing: 301243095.xml

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301220029.xml

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301198021.xml

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301173818.xml

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q42019 on Jan. 22, 2020 Original Filing: 301129643.xml

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301128291.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2019. Original Filing: 301077924.xml

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 22, 2019. Original Filing: 301057571.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 22, 2019. Original Filing: 301035659.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301016948.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2018. Original Filing: 300996624.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2018. Original Filing: 300975042.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2018. Original Filing: 300957227.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2018. Original Filing: 300935212.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300913932.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300895303.xml

Lobbying Issues

340B (no specific bill), Hepatitis C (general education; no specific bill), Human papilloma virus and vaccine policies (general education; first dollar coverage; preventative services), shingles vaccine policies (general education), antimicrobial resistance (general education), biosimilars (no specific bill), cost and value of medicines (no specific bill), women's health (general education), Prescription Drug User Fee Act (PDUFA; general education), Affordable Care Act, general pharmaceutical issues (transparency, formulary design, prescription drug coverage), H.R. 1628 - American Health Care Act of 2017, Implementation of P.L.114-255 - 21st Century Cures Act, S.204/H.R.878 - Trickett Wendler Right to Try Act of 2017, S. 469 - Affordable and Safe Prescription Drug Importation Act, S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q12017 on July 20, 2017 Original Filing: 300896710.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2017. Original Filing: 300874902.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 23, 2017. Original Filing: 300857656.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300839047.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300821430.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2016. Original Filing: 300799914.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2016. Original Filing: 300781933.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q32015 on Feb. 1, 2016 Original Filing: 300785857.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2015. Original Filing: 300758695.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300743991.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 20, 2015. Original Filing: 300722830.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q42014 on March 25, 2015 Original Filing: 300711927.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, Merck & Co, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300703634.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q32014 on Sept. 6, 2016 Original Filing: 300824239.xml

Lobbying Issues

340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q32014 on Oct. 7, 2015 Original Filing: 300751145.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Amendment

Merck & Co, Inc. amended a lobbying report for in-house lobbying in Q32014 on Jan. 26, 2015 Original Filing: 300709576.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, Merck & Co, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300684965.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, Merck & Co, Inc. had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300667051.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, Merck & Co, Inc. had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300644891.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, MERCK & CO, INC had in-house lobbyists. The report was filed on Jan. 17, 2014. Original Filing: 300617989.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, MERCK & CO, INC had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300606266.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, MERCK & CO, INC had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300582161.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Amendment

MERCK & CO, INC amended a lobbying report for in-house lobbying in Q12013 on Oct. 21, 2013 Original Filing: 300607034.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, MERCK & CO, INC had in-house lobbyists. The report was filed on April 19, 2013. Original Filing: 300557206.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, MERCK & CO, INC had in-house lobbyists. The report was filed on Jan. 18, 2013. Original Filing: 300534867.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, MERCK & CO, INC had in-house lobbyists. The report was filed on Oct. 19, 2012. Original Filing: 300513832.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, MERCK & CO, INC had in-house lobbyists. The report was filed on July 19, 2012. Original Filing: 300491360.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, MERCK & CO, INC had in-house lobbyists. The report was filed on April 20, 2012. Original Filing: 300471078.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, MERCK & CO, INC had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300450704.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, MERCK & CO, INC had in-house lobbyists. The report was filed on Oct. 20, 2011. Original Filing: 300428268.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, MERCK & CO, INC had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300402363.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, MERCK & CO, INC had in-house lobbyists. The report was filed on April 20, 2011. Original Filing: 300378564.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, MERCK & CO, INC had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300355176.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, MERCK & CO, INC had in-house lobbyists. The report was filed on Oct. 20, 2010. Original Filing: 300324342.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Amendment

MERCK & CO, INC amended a lobbying report for in-house lobbying in Q22010 on July 20, 2010 Original Filing: 300301365.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, MERCK & CO, INC had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300299485.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Amendment

MERCK & CO, INC amended a lobbying report for in-house lobbying in Q22010 on July 20, 2010 Original Filing: 300300787.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Amendment

MERCK & CO, INC amended a lobbying report for in-house lobbying in Q12010 on May 17, 2011 Original Filing: 300384078.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, MERCK & CO, INC had in-house lobbyists. The report was filed on April 19, 2010. Original Filing: 300265443.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, MERCK & CO, INC had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300246647.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, MERCK & CO, INC had in-house lobbyists. The report was filed on Oct. 20, 2009. Original Filing: 300219649.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, MERCK & CO, INC had in-house lobbyists. The report was filed on July 20, 2009. Original Filing: 300187507.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, MERCK & CO, INC had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300162098.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, MERCK & CO, INC had in-house lobbyists. The report was filed on Jan. 21, 2009. Original Filing: 300130846.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, MERCK & CO, INC had in-house lobbyists. The report was filed on Oct. 17, 2008. Original Filing: 300097263.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, MERCK & CO, INC had in-house lobbyists. The report was filed on July 18, 2008. Original Filing: 300073958.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, MERCK & CO, INC had in-house lobbyists. The report was filed on April 18, 2008. Original Filing: 300045436.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed